SCHEMBL711708

SCHEMBL711708

O=S(=O)(Nc1nccs1)c1ccc(Nc2cc(C3CC3)nn2-c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 8/20 0.52
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
ALDH1A1 P00352 1/20 0.49
SCN3A Q9NY46 5/20 0.49
SCN5A Q14524 3/20 0.48
POLB P06746 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MAPT P10636 1/20 0.48
PKM P14618 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
BLM P54132 1/20 0.48
CTDSP1 Q9GZU7 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
SCN8A Q9UQD0 3/20 0.47
EGFR P00533 1/20 0.46
KDR P35968 1/20 0.46
SCN1A P35498 2/20 0.46
SCN4A P35499 1/20 0.46
SCN2A Q99250 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL710177 0.87 SCN9A (0.54) SCN9ASCN3ASCN5ASCN8ASCN1A
SCHEMBL712466 0.87 SCN9A (0.49) SCN9ASCN3ASCN5ASCN8ASCN1A
SCHEMBL712299 0.85 SCN9A (0.68) SCN9AMEN1KMT2AALDH1A1SCN3A
SCHEMBL713753 0.80 CYP2C9 (0.57) SCN9AMEN1KMT2AALDH1A1SCN3A
SCHEMBL710057 0.76 SMN1; SMN2 (0.60) SCN9AMEN1KMT2ASCN3AMAPT
SCHEMBL712390 0.73 SCN9A (0.55) SCN9AKMT2AALDH1A1SCN3ASCN5A
SCHEMBL710624 0.73 SCN9A (0.55) SCN9AMEN1KMT2AALDH1A1SCN5A
SCHEMBL711730 0.73 SCN9A (0.55) SCN9AKMT2ASCN3ASCN5ASCN8A
Sulfazamet SCHEMBL28264721 0.72 SCN9A (0.67) SCN9AMEN1KMT2AALDH1A1SCN5A
SCHEMBL711153 0.72 SCN9A (0.52) SCN9ASCN3ASCN5ASCN8ASCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A SCN9A 17/4885MEN1 4426/4885KMT2A 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.